ABSTRACT IMSCOGS Conference 2016:

Cognition, patient reported behavioral outcomes (PRO) and adherence in MS patients on dimethyl fumarate – a 12-month observational study in German MS practice centers

Thaler L¹, Scholl S¹, Roßnagel F², Wehrle K², Ngouongo S², Schlegel S³, Lang M²,4, Bergmann A², Schreiber H²,4

¹ Ulm University, Medical Faculty, Albert Einsteinstraße 1, D-89081 Ulm
² NeuroTransData (NTD) study group on Multiple Sclerosis, D-86633 Neuburg
³ Ulm University, Institute for Biomedical Statistics and Epidemiology, D-89075 Ulm
⁴ Neuropoint Patient Academy, D-89073 Ulm

Background: The long-term stability of cognitive and psycho-behavioral factors is an eminent treatment goal in MS patients, since they have a significant impact on their quality of life (QoL).

Objectives: (1) to longitudinally document cognition, clinical evolution and patient-reported behavioural outcomes (PRO) in patients with relapsing-remitting multiple sclerosis (RRMS) treated with Tecfidera® as first-line treatment or changing from other baseline therapies (2) to identify factors exerting significant influence on adherence.

Methods: Interim analysis of a prospective, multi-center, open-label registry study of 24 months with assessments at baseline/BL and after 3, 6, 9,12, 18 and 24 months follow-up (T3, T6, T9, T12, T18, T24). At T12 follow-up, 609 RRMS patients (Mc Donald) on TecfideraR (mean age: 41.1 yr, 73% female, median EDSS 2.0) entered analysis. Outcomes: adherence rate, clinical/mobility (EDSS, ambulation index, 2-minute walk test/TMWT), cognition battery (BICAMS) indexing processing
speed/SDMT, verbal/CVLT and visual/spatial memory/BVMT-R), and PROs representing treatment satisfaction (TSQM-9), depression (BDI), anxiety (STAI X1/2), fatigue (FSMC), QoL (EQ-5D), disease coping (FKV), personality (NEO-FFI) and life-satisfaction (FLZ).

Results: At T12 months follow-up, all cognitive parameters (sum scores of SDMT, CVLT and BVMT-R) had remained stable within normal ranges. In BL vs. T12, increased QoL (EQ-5D: 73,3 vs. 75,2) and treatment satisfaction (TSQM 9: 46,0 vs. 48,8), as well as slightly decreased scores of state anxiety (STAI X1: 39,5 vs. 38,8) and depression (BDI: 2,49 vs. 2,41) were observed with dimethyl fumarate. Only fatigue distinctly aggravated over time (FSMC: 53,8 vs. 57,6). We found non-adherence in 24,5 % of patients, and significantly more frequent in women than in men (OR 3,0). The major reason for non-adherence was gastrointestinal (GI) side effects (26,9%). Univariate logistic regression analysis (cut-off: 0,25) identified gender, fatigue, state anxiety, depression, QoL, treatment satisfaction, number of premedications and life-satisfaction as significant determinates of influence.

Conclusion: (1) Except for fatigue, dimethyl fumarate is effective stabilizing cognitive and behavioral variables in early RRMS (2) Non-adherences in women is there show a three times higher non-adherence rate than men which may be due to more susceptibility to GI side effects. (3) Behavioral factors are emerging as determinates of adherence.

The study was supported by an investigational grant from Biogen